Karan Rao

ORCID: 0000-0003-4689-9982
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Cardiac Valve Diseases and Treatments
  • Cardiac pacing and defibrillation studies
  • Cardiac Imaging and Diagnostics
  • Cardiac Arrhythmias and Treatments
  • Infective Endocarditis Diagnosis and Management
  • Cardiac electrophysiology and arrhythmias
  • Atrial Fibrillation Management and Outcomes
  • Viral Infections and Immunology Research
  • Cardiomyopathy and Myosin Studies
  • Cardiovascular and Diving-Related Complications
  • Cardiovascular Function and Risk Factors
  • Congenital Heart Disease Studies
  • Respiratory Support and Mechanisms
  • ECG Monitoring and Analysis
  • Foreign Body Medical Cases
  • Adenosine and Purinergic Signaling
  • Housing, Finance, and Neoliberalism
  • Williams Syndrome Research
  • Chronic Obstructive Pulmonary Disease (COPD) Research
  • Abdominal vascular conditions and treatments
  • Mechanical Circulatory Support Devices
  • Esophageal and GI Pathology
  • Neurogenetic and Muscular Disorders Research
  • Genetic Associations and Epidemiology
  • Management of metastatic bone disease

Royal North Shore Hospital
2022-2025

The University of Sydney
2020-2025

Cooperative Trials Group for Neuro-Oncology
2024

Hindustan Institute of Technology and Science
2024

Concord Repatriation General Hospital
2023

University of Iowa
2023

University of Iowa Hospitals and Clinics
2023

Society of Interventional Radiology
2022

Westmead Hospital
2017-2022

Westmead Institute
2022

Background Patent foramen ovale (PFO)-associated platypnea-orthodeoxia syndrome is characterized by dyspnea and hypoxemia when upright. The pathogenesis thought to involve an increase in right atrial pressure or change degree of left shunting with upright posture. Methods Results We sought characterize patients related PFO without pulmonary hypertension. retrospectively reviewed databases at 3 tertiary referral hospitals New South Wales, Australia from 2000 2019. Fourteen a mean age 69±14...

10.1161/jaha.121.024609 article EN cc-by-nc-nd Journal of the American Heart Association 2022-07-25

Aortic stenosis is the most common cardiac valve pathology worldwide and has a mortality rate of over 50% at 5 years if left untreated. Transcatheter aortic implantation (TAVI) minimally invasive highly effective alternative treatment option to open-heart surgery. High-grade atrioventricular conduction block (HGAVB) one complications after TAVI requires permanent pacemaker. Due this, patients are typically monitored for 48 hours post TAVI, however up 40% HGAVB may delayed, occur discharge....

10.1136/bmjopen-2022-070219 article EN cc-by-nc BMJ Open 2023-03-01

We present a patient with symptomatic severe aortic stenosis and atrial fibrillation complicated by tachycardia-bradycardia syndrome, deemed too high-risk for surgical valve replacement referred transcatheter replacement. show that concurrent implantation of leadless pacemaker system can be performed successfully minimal additional risk to the patient, also, it used rapidly pace ventricles assist in balloon valvuloplasty prosthetic deployment.

10.1016/j.cjco.2020.11.015 article EN cc-by-nc-nd CJC Open 2020-11-26

Abstract Background Aortic stenosis (AS) may prolong atrioventricular (AV) conduction secondary to calcium infiltration of the atrioventricular-His-pathway, which is hypothesized contribute bradyarrhythmia and sudden cardiac death in this cohort. This study investigates correlation between calcific AS impaired AV conduction. Methods We performed an observational Mendelian randomization (MR). The was a sub-analysis on patients undergoing transcatheter aortic valve implantation2021-2023)....

10.1101/2024.05.08.24307094 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2024-05-10

Introduction: Large observational and Mendelian randomization (MR) studies have demonstrated a strong association between elevated triglycerides (TG) risk of aortic stenosis (AS). However, at present there remains no evidence for the use lipid-lowering therapies to prevent or treat AS. To address this gap, we used drug target MR approach investigate whether emerging TG lowering may reduce Methods: We collected summary statistics levels AS from genome-wide including 1,253,277 653,867 European...

10.1161/circ.150.suppl_1.4138335 article EN Circulation 2024-11-12
Coming Soon ...